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RESULTS: Usable response rate was 37% (n = 363). Mean A1C
was 7.2 (SD 1.4), mean diabetes duration was 10.2 (SD 9.1)
years, 62.1% were obese (BMI >30), and about 42% used
insulin. Mean (SD) and range of EQ-5D index scores were:
0.71(0.21), −0.04 to 1.00 for the US; 0.60(0.32), −0.48 to 1.00
for the UK. Spearman’s correlation between US and UK scores
was 0.998 (p < 0.001). A paired samples t-test indicated that the
US valuations were signiﬁcantly higher (p < 0.001) with the mean
difference being 0.11(0.11). In individual OLS regressions, those
with neurological complications, ischemic heart disease, obesity
or depressive symptoms had signiﬁcantly higher EQ-5D US
scores as well as UK scores. These conditions also signiﬁcantly
predicted greater differences between US and UK scores. CON-
CLUSION: Although well correlated, the U.S population means
were signiﬁcantly higher than UK population means, and this
difference was seen across clinically relevant categories in
T2DM. The preference scoring system employed may therefore
inﬂuence results of research conducted using the EQ-5D instru-
ment to measure preferences.
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OBJECTIVES: Regulatory agencies demand QALYs as evidence
of effectiveness in economic evaluation. This is a challenge for
clinical studies in which outcomes are measured using condition-
speciﬁc instruments that lack the required measurement proper-
ties. This study aims to provide a model for deriving EQ-5D
utilities directly from the QoL-AGHDA. These estimates were
used to calculate QALY deﬁcit and treatment effects in adults
with GHD in relation to the general population values.
METHODS: A UK postal survey captured QoL-AGHDA (a con-
dition-speciﬁc measure for patients with GHD) and EQ-5D
responses from a broadly representative sample of the general
population (n = 921). These data were used to construct two-
step regression model (R2 = 0.42). In the ﬁrst, TTO-weighted ED-
5Dindex was the dependent variable and yes/no responses to all 25
QoL-AGHDA items were coded as dichotomous dummy vari-
ables (xi). In the second step utilities were computed as follows:
QoL-AGHDAutility = b0 + c*age + Σbi*xi + ei. QoL-AGHDAutility
at yearly visits for 894 UK patients followed in the KIMS data-
base was computed using the same regression model. Subse-
quently the mean QALY over time were compared to baseline
values and assessed in relation to the cross-sectional age/gender
population values. RESULTS: Health related quality of life mea-
sured by QoL-AGHDAutility in patients prior to GH replacement
differed signiﬁcantly from age/gender-matched values in the
general population (0.67 vs. 0.85, p < 0.0001). After the ﬁrst
year of treatment the deﬁcit was reduced to −0.07. Despite a dra-
matic improvement during the ﬁrst year of treatment, patients’
health status remained signiﬁcantly different from general pop-
ulation reference values (p < 0.001) over the course of their treat-
ment. Nevertheless, a mean undiscounted gain from baseline of
0.32 QALYs was seen in the treated patients, corresponding to
0.08 QALYs per year. CONCLUSION: Estimates of treatment
beneﬁt for use in economic evaluation can be successfully derived
from condition-speciﬁc measures.
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OBJECTIVES: To evaluate the impact of Generalized Anxiety
Disorder (GAD) on diagnosed comorbidities, medication use and
treatment costs. METHODS: Claims were drawn from Phar-
Metrics Integrated Outcomes Database for 12-month prior and
post the ﬁrst GAD (ICD9-CM: 30002) diagnosis between
Janaury 2003 and June 2004 (the diagnosis date as the index
date). No GAD diagnosis 12-month prior the index date, 24-
month continuous insurance eligibility and aged 18–64 were
required. Changes in diagnoses of comorbidities, medication use
patterns, and treatment costs between the year before and after
the index date were examined. Comparison among subgroups of
GAD patients with comorbid depression and pain was also inves-
tigated. Wilcoxon Signed Rank test and McNemar’s test were
used to examine pre-post differences for continuous and cate-
gorical variables, respectively. RESULTS: A total of 240,041
patients were included in this study. The mean age was 41.7 years
old and 67% were female. After diagnosis of GAD, a signiﬁ-
cantly higher percent of patients were diagnosed with depression
(44.4% vs. 30.9%, p < 0.001), dyslipidemia (24.0% vs.19.9%,
p < 0.001), and diabetes (6.1% vs. 5.3%, p < 0.001) than before
GAD diagnosis. The use of antidepressants increased from
42.3% to 56.8% (p < 0.001). Compared to the year prior to
GAD diagnosis, total annual costs increased by $2034 (p <
0.001) driven mainly by increases of inpatient and outpatient
costs ($285 and $773, p < 0.001, GAD only and increased
merely $306 for GAD patients with depression while GAD
patients with pain and those with both pain and depression
increased by $2253 and $4665 (both p < 0.001), respectively.
CONCLUSION: Diagnosis of GAD had signiﬁcant impact on
comorbidities, medication use and treatment costs. Furthermore,
comorbid pain and depression had substantial extra burden on
GAD patients as compared with those had GAD only. Recog-
nizing these comorbidities is important in the treatment of
patients with GAD.
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